HRS 7450
Alternative Names: HRS-7450Latest Information Update: 12 Jun 2024
At a glance
- Originator Fujian Shengdi Pharmaceutical
- Class Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Stroke
Most Recent Events
- 12 Jun 2024 Fujian Shengdi Pharmaceutical plans a phase I trial for Acute ischemic storke in China (Injection) in June 2024 (NCT06447415)
- 17 Oct 2023 Preclinical trials in Stroke in China (Parenteral)
- 17 Oct 2023 Fujian Shengdi Pharmaceutical plans a phase-I trial for Stroke (In Chinese volunteers) (NCT06087094)